Skip to main navigation

Investors

News Archive
Past Events and Presentations
Stock History

News Archive

News Archive

Items Per Page

Year

Mar 19, 2020

Mylan Ramps Up U.S. Manufacturing of Hydroxychloroquine Sulfate Tablets to Meet Potential COVID-19 Patient Needs

Mar 10, 2020

Mylan Wins District Court Decision Against Sanofi's Lantus® SoloSTAR® Patent

Mar 10, 2020

Mylan Pharmaceuticals ULC Launches Wixela® Inhub® (fluticasone propionate and salmeterol inhalation powder, USP), the First Available Bioequivalent Alternative to ADVAIR® DISKUS® (fluticasone propionate and salmeterol inhalation powder) in Canada

Mar 09, 2020

U.S. FDA Accepts Biologics License Application (BLA) for Mylan and Biocon's Proposed Biosimilar Bevacizumab for Review

Feb 27, 2020

Mylan Reports Fourth Quarter and Full Year 2019 Results and Provides 2020 Guidance

Feb 27, 2020

Mylan and Pfizer Announce Appointment of Viatris Chief Financial Officer

Feb 27, 2020

Mylan and Pfizer Finalize Appointments to Viatris Board of Directors

Feb 18, 2020

Mylan to Release 2019 Fourth Quarter, Full Year Results and 2020 Guidance on Feb. 27, 2020

Jan 08, 2020

Mylan Initiates Voluntary Nationwide Recall of Three Lots of Nizatidine Capsules, USP, Due to the Detection of Trace Amounts of NDMA (N-Nitrosodimethylamine) Impurity Found in the Active Pharmaceutical Ingredient Manufactured by Solara Active Pharma Scien

Jan 06, 2020

Mylan to Present at the 38th Annual J.P. Morgan Healthcare Conference

Pagination

First page
Previous page
Page 1
Page 2
Page 3
Page 4
Current page 5
Page 6
Page 7
Page 8
Page 9
…
Next page
Last page

Share

Utility Nav

Privacy Statement
Terms and Conditions

©2024 Mylan N.V. All rights reserved. The Mylan logo is a registered trademark of Mylan Inc.